To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers

This is a prospective, non-randomised, open label, Phase I, dose escalation study of plerixafor (MozobilTM) in patients with histological documentation of advanced pancreatic, high grade serous ovarian or colorectal adenocarcinoma. We will investigate the feasibility of administering plerixafor in terms of safety, and will try to identify the proof of mechanism in patients.

This study is required to establish whether relevant plasma concentrations of plerixafor can be achieved safely in patients with advanced pancreatic, high grade serous ovarian and colorectal cancer.

Plerixafor (Mozobil) will be administered as a continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr (as an inpatient for at least the initial 48 hours). 3 patients will be entered sequentially (at least 1 week apart), using a standard 3+3, Phase I trial design. Up to 28 patients will be recruited.

Inclusion criteria

• Aged 16 years or over at the time of signing informed consent form.
• Dose escalation phase only: Patients with inoperable, histologically proven locally advanced or metastatic pancreatic, high grade serous ovarian or colorectal adenocarcinoma, refractory to conventional chemotherapy or a patient who has declined conventional chemotherapy. OR;
• Expansion phase only: Patients with inoperable, histologically proven locally advanced or metastatic pancreatic, refractory to conventional chemotherapy or a patient who has declined conventional chemotherapy.
• Tumour lesions considered to be accessible for core biopsy and immunostaining assessment.
• ECOG performance status 0-1.
• Life expectancy of at least 12 weeks.
• All women of child-bearing potential and all sexually active male patients must agree to use effective contraception methods throughout the study and for 3 months after the final dose of study drug.

Exclusion criteria

• Inadequate haematological function defined by:
• Absolute neutrophil count (ANC) <1.5 x 109/L
• Absolute lymphocyte count < normal level for institution
• Haemoglobin <9.0 g/dL (90 g/L) (may be increased to this level with transfusion as long as there is no evidence of active bleeding)
• Platelets <100 x 109/L
• Clotting; INR >1.3
• Inadequate renal function defined by calculated creatinine clearance by Cockcroft-Gault of <50 ml/min.
• Inadequate hepatic function defined by:
• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x upper limit of normal (ULN) or >5 x in the presence of liver metastases
• Total bilirubin >1.5 x ULN
• Current treatment (within 28 days of entry) with chemotherapy, steroids or other immunosuppressive drugs.
• Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality which in the judgment of the Investigator would place the patient at undue risk or interfere with the study.
• Cardiac co-morbidity:
• Past history of significant rhythm disturbance (e.g. SVT, AF or ventricular irregularities)
• Requirement for pacemaker.
• Myocardial infarction in the previous 6 months.
• Known medical history of proven postural hypotension.
• Active infection.
• Patients with known allergy to plerixafor or its excipients.
• Patients known to have hepatitis B, hepatitis C or HIV infection.
• Women, who are pregnant, plan to become pregnant or are lactating (during the study or for up to 3 months after the last dose)